

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY

Health systems, medical products and innovation **Medical products: quality, safety, innovation** 

Brussels, 14<sup>th</sup> January 2019

## HTA NETWORK STAKEHOLDER POOL AGENDA

### 16 JANUARY 2019, BRUSSELS

#### Albert Borschette Congress Center (CCAB) Room AB-4B

- **09.30** Registration and welcome coffee
- 10.30- 11.15Welcome and Update on EU cooperation on HTA<br/>Welcome by Andrzej Rys, Director, DG SANTE. Update by Head of<br/>Sector HTA, DG SANTE

# **11.15 -12.30 EUnetHTA Update on current and future stakeholder** involvement EUnetHTA Secretariat and Work Package representatives

The representatives of the EUnetHTA Joint Action will provide a general update on the work related to the involvement of stakeholders, plans for 2019; as well as information on the latest development of the relevant Work Packages on Joint Assessments and Early Dialogues.

- 12.30 13.30 Lunch Break
- 13.30 15.00 Parallel sessions

### The following three sessions take place in parallel

# Group A: Patient and health care professional experts' involvement in the joint HTA work

Chair: DG SANTE and BEUC

The first part of the session will start with a scene setter by EURORDIS, as a representative of patients in the Stakeholder Pool. The following issues will be discussed related to the involvement of patient and clinical experts in joint HTA work:

**Q1.** What are the key issues in the systematic engagement of patients in the procedures – early dialogue and joint assessment (e.g. systemic vs ad hoc engagement, role of the patients)?

**Q2.** Practical implementation. How are patients identified (e.g. European vs national base), contacted (e.g. timing,); introduced to the procedure; and mentored (consider

existing best engagement practices)? How can patient organisations prepare and optimise involvement?

**Q3.** Impact: How is EUnetHTA measuring the impact of patient engagement (e.g. follow up on issues raised by patients), also with a view to uptake?

<u>Background document</u>: Joint Statement Patients Call for a Meaningful Involvement in European Cooperation on HTA

# Group B PHARMA: Cooperation on identification and prioritisation of health technologies for Joint work

### Chair: EUnetHTA JA and EFPIA

The discussion is expected to focus on possibilities of information sharing between the industry and EUnetHTA, with the objective of early identification of relevant technologies for joint assessment. A presentation from EFPIA, as a representative of pharmaceutical industry in the Stakeholder Pool, will set the scene; EunetHTA will present targeted questions to initiate the discussion.

# Group B MEDTECH: Cooperation on identification and prioritisation of health technologies for Joint work

### Chair: DG SANTE and MedTech Europe TBC

For medical technologies, the discussion is expected to focus on prioritising technologies throughout the early phases of the product cycle (horizon scanning and identifying technologies for joint assessment and early dialogues). EunetHTA will provide an update on the planned an on-going work of EunetHTA on topic identification and prioritisation. DG SANTE will present a short scene setter.

**Q1.** What are the possible sources of information for the early identification of technologies? What input could industry, clinicians and other stakeholders provide?

**Q2.** What should be the key criteria for filtering and prioritising products during horizon scanning and for joint work – possibly exploring the concept of transformative technologies?

**Q3.** What should be included in the minimal datasets, the main output of the horizon scanning exercise produced for each technology (e.g. description of the technology name, developer, the intended indication for use, the developmental status (availability of clinical trials and if applicable phase) and regulatory status)?

## 15.00 – 15.45 Feedback and discussion from parallel sessions

For each of the three parallel sessions, a short feedback if foreseen by the chairs followed by a discussion in the plenary.

15.45- 16.00

### **Closure of the meeting**